

**STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD**

IN THE MATTER OF RULEMAKING : REPORT TO THE LEGISLATURE
PROCEEDINGS BEFORE THE : CR 26-034
CONTROLLED SUBSTANCES BOARD :

I. THE PROPOSED RULE: The proposed rule, including the analysis and text, is attached.

II. REFERENCE TO APPLICABLE FORMS: N/A

III. FISCAL ESTIMATE AND EIA: The Fiscal Estimate and EIA is attached.

IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:

This rule schedules N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats N-pyrrolidino metonitazene and N-pyrrolidino protonitazene under chapter 961, Stats. by creating the following:

CSB 2.014 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I. Section 961.14 (2) (xm) 8e. and 8m., Stats., are created to read:

961.14 (2) (xm) 8e. N-pyrrolidino metonitazene also known as metonitazepyne (2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

961.14 (2) (xm) 8m. and N-pyrrolidino protonitazene also known as protonitazepyne (5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

The Affirmative Action order, dated September 29, 2025, took effect on October 6, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.

V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD'S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:

Per s. 961.11(4), Stats., if no objection is made, the board shall promulgate a final rule for which notice of proposed rulemaking is omitted. Therefore, the Board did not hold a public hearing. No other public comments were received.

VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS:

Legislative Council Staff did not make any recommendations.

**VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY
ANALYSIS: N/A**

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	PROPOSED ORDER OF THE
PROCEEDINGS BEFORE THE	:	CONTROLLED SUBSTANCES BOARD
CONTROLLED SUBSTANCES BOARD	:	ADOPTING RULES
	:	(CLEARINGHOUSE RULE 26-034)

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.014, relating to scheduling 2 Synthetic Benzimidazole-Opioids.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: s. 961.14, Stats.

Statutory authority: s. 961.11 (1) and (4), Stats.

Explanation of agency authority:

Section 961.11 (1), Stats. provides that “[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227.”

Section 961.11(4), Stats. provides that “[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30–day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).”

Related statute or rule: s. 961.14, Stats.

Summary of, and comparison with, existing or proposed federal regulation:

On August 15, 2025, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding N-pyrrolidino metonitazene and N-pyrrolidino protonitazene to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 15, 2025.

Plain language analysis:

This rule schedules N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats N-pyrrolidino metonitazene and N-pyrrolidino protonitazene under chapter 961, Stats. by creating the following:

CSB 2.014 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I. Section 961.14 (2) (xm) 8e. and 8m., Stats., are created to read:

961.14 (2) (xm) 8e. N-pyrrolidino metonitazene also known as metonitazepyne (2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

961.14 (2) (xm) 8m. and N-pyrrolidino protonitazene also known as protonitazepyne (5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

The Affirmative Action order, dated September 29, 2025, took effect on October 6, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: No comments were received.

Comparison with rules in adjacent states:

Illinois: Illinois has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [720 Illinois Compiled Statutes 570 Section 204].

Iowa: Iowa has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [Iowa Code 124.204].

Michigan: Michigan has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [Michigan Compiled Laws s. 333.7212].

Minnesota: Minnesota has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [Minnesota Statutes 152.02 (2)].

Summary of factual data and analytical methodologies:

The methodology was to schedule N-pyrrolidino metonitazene and N-pyrrolidino protonitazene to conform with the federal Controlled Substances Act.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:

The proposed rule was posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals. No comments were received.

Fiscal Estimate and Economic Impact Analysis:

The fiscal estimate and economic impact analysis is attached.

Effect on small business:

These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Jennifer.Garrett@wisconsin.gov, or by calling (608) 266-2112.

Agency contact person:

Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 14497, Madison, Wisconsin 53708-0497; email at DSPSAdminRules@wisconsin.gov.

TEXT OF RULE

SECTION 1. CSB 2.014 is created to read:

CSB 2.014 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I. Section 961.14 (2) (xm) 8e. and 8m., Stats., are created to read:

961.14 (2) (xm) 8e. N-pyrrolidino metonitazene also known as metonitazepyne (2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

961.14 (2) (xm) 8m. and N-pyrrolidino protonitazene also known as protonitazepyne (5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)

This Proposed Order of the Controlled Substances Board is approved for submission to the Governor and Legislature.

Dated 07/23/2026

Agency *Douglas Englebert*
Chairperson
Controlled Substances Board

ADMINISTRATIVE RULES

Fiscal Estimate & Economic Impact Analysis

1. Type of Estimate and Analysis ☒ Original ☐ Updated ☐ Corrected	2. Date 5/26/26								
3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable) CSB 2.014									
4. Subject Scheduling 2 Synthetic Benzimidazole-Opioids									
5. Fund Sources Affected ☐ GPR ☐ FED ☒ PRO ☐ PRS ☐ SEG ☐ SEG-S	6. Chapter 20, Stats. Appropriations Affected s. 20.165 (1) (g) (hg)								
7. Fiscal Effect of Implementing the Rule <table style="width: 100%;"><tr><td>☐ No Fiscal Effect</td><td>☒ Increase Existing Revenues</td><td>☐ Increase Costs</td><td>☐ Decrease Costs</td></tr><tr><td>☐ Indeterminate</td><td>☐ Decrease Existing Revenues</td><td colspan="2">☐ Could Absorb Within Agency's Budget</td></tr></table>		☐ No Fiscal Effect	☒ Increase Existing Revenues	☐ Increase Costs	☐ Decrease Costs	☐ Indeterminate	☐ Decrease Existing Revenues	☐ Could Absorb Within Agency's Budget	
☐ No Fiscal Effect	☒ Increase Existing Revenues	☐ Increase Costs	☐ Decrease Costs						
☐ Indeterminate	☐ Decrease Existing Revenues	☐ Could Absorb Within Agency's Budget							
8. The Rule Will Impact the Following (Check All That Apply) <table style="width: 100%;"><tr><td>☐ State's Economy</td><td>☐ Specific Businesses/Sectors</td></tr><tr><td>☐ Local Government Units</td><td>☐ Public Utility Rate Payers</td></tr><tr><td colspan="2">☐ Small Businesses (if checked, complete Attachment A)</td></tr></table>		☐ State's Economy	☐ Specific Businesses/Sectors	☐ Local Government Units	☐ Public Utility Rate Payers	☐ Small Businesses (if checked, complete Attachment A)			
☐ State's Economy	☐ Specific Businesses/Sectors								
☐ Local Government Units	☐ Public Utility Rate Payers								
☐ Small Businesses (if checked, complete Attachment A)									
9. Estimate of Implementation and Compliance to Businesses, Local Governmental Units and Individuals, per s. 227.137(3)(b)(1). \$0									
10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be \$10 Million or more Over Any 2-year Period, per s. 227.137(3)(b)(2)? ☐ Yes ☒ No									
11. Policy Problem Addressed by the Rule This rule schedules N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats N-pyrrolidino metonitazene and N-pyrrolidino protonitazene under chapter 961, Stats. by creating the following: CSB 2.014 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I. Section 961.14 (2) (xm) 8e. and 8m., Stats., are created to read: 961.14 (2) (xm) 8e. N-pyrrolidino metonitazene also known as metonitazepyne (2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole). 961.14 (2) (xm) 8m. and N-pyrrolidino protonitazene also known as protonitazepyne (5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole). The Affirmative Action order, dated September 29, 2025, took effect on October 6, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.									
12. Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals that may be Affected by the Proposed Rule that were Contacted for Comments. The proposed rule was posted on the DSPS Website for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals. No comments were received.									
13. Identify the Local Governmental Units that Participated in the Development of this EIA. None.									

ADMINISTRATIVE RULES

Fiscal Estimate & Economic Impact Analysis

14. Summary of Rule's Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred)

DSPS estimates a total of \$4,800.00 in one-time costs to implement the rule. The estimated need for 0.1 limited term employee (LTE) is for internal review and consultation, rule promulgation, board meeting preparation and annual reporting. The one-time costs cannot be absorbed in the currently appropriated agency budget.

15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule

The benefit is that the federal and state controlled substances acts will be uniform to avoid stakeholder confusion.

16. Long Range Implications of Implementing the Rule

The long range implications of implementing the rule are that N-pyrrolidino metonitazene and N-pyrrolidino protonitazene will be added to Wis. Stat. ch. 961 as a schedule I controlled substances.

17. Compare With Approaches Being Used by Federal Government

On August 15, 2025, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding N-pyrrolidino metonitazene and N-pyrrolidino protonitazene to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 15, 2025.

18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minnesota)

Illinois: Illinois has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [720 Illinois Compiled Statutes 570 Section 204].

Iowa: Iowa has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [Iowa Code 124.204].

Michigan: Michigan has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [Michigan Compiled Laws s. 333.7212].

Minnesota: Minnesota has not listed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances [Minnesota Statutes 152.02 (2)].

19. Contact Name	20. Contact Phone Number
Nilajah Hardin, Administrative Rules Coordinator	608-267-7139

This document can be made available in alternate formats to individuals with disabilities upon request.

ADMINISTRATIVE RULES
Fiscal Estimate & Economic Impact Analysis

ATTACHMENT A

1. Summary of Rule's Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)

2. Summary of the data sources used to measure the Rule's impact on Small Businesses

3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?

- ☐ Less Stringent Compliance or Reporting Requirements
☐ Less Stringent Schedules or Deadlines for Compliance or Reporting
☐ Consolidation or Simplification of Reporting Requirements
☐ Establishment of performance standards in lieu of Design or Operational Standards
☐ Exemption of Small Businesses from some or all requirements
☐ Other, describe:

4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses

5. Describe the Rule's Enforcement Provisions

6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)

☐ Yes ☐ No
